All Stories

  1. White matter microstructure and theory of mind in clinical high risk for psychosis: a discovery-replication study
  2. Comparative profiles of anomalous self-experiences and social cognition in clinical high risk for psychosis and autism spectrum disorder
  3. Is emotion regulation a mechanism of change in virtual reality-assisted therapy for auditory hallucinations? Secondary analyses of the CHALLENGE randomized clinical trial
  4. Individual Profiling Across the Psychosis Continuum using Affinity Scores
  5. Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis
  6. Subtle impairments of facial emotion expressions in individuals at ultra-high risk for psychosis
  7. Study protocol for a randomized clinical pilot trial investigating feasibility and efficacy of augmenting a virtual reality-assisted intervention targeting auditory verbal hallucinations with biofeedback: The Neuro-VR study
  8. Whole-brain functional connectivity predicts ultra-high risk for psychosis status and level of functioning
  9. Resting-state electroencephalography microstates in antipsychotic-naïve individuals across the psychosis spectrum
  10. Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study
  11. Alleviating negative symptoms in schizophrenia using a virtual reality-based therapy targeting social reward learning (ENGAGE): Protocol for a randomised, controlled, assessor-blind pilot study
  12. Study protocol for a randomized clinical pilot trial investigating feasibility and efficacy of augmenting a virtual reality-assisted intervention targeting auditory verbal hallucinations with biofeedback: the Neuro-VR study
  13. Alleviating negative symptoms in schizophrenia using a Virtual Reality-based therapy targeting social reward learning (ENGAGE): Protocol for a randomised, controlled, assessor-blind pilot study
  14. Cognitive profiles across the psychosis continuum
  15. Publisher Correction: Structural and functional connectivity in relation to executive functions in antipsychotic-naïve patients with first episode schizophrenia
  16. Structural and functional connectivity in relation to executive functions in antipsychotic-naïve patients with first episode schizophrenia
  17. Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk
  18. Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
  19. Brief rapport: Perceptual aberration in patients at ultra‐high risk for psychosis
  20. Associations between saliva alpha-amylase, heart rate variability, saliva cortisol and cognitive performance in individuals at ultra high-risk for psychosis
  21. Fibre density and fibre-bundle cross-section of the corticospinal tract are distinctly linked to psychosis-specific symptoms in antipsychotic-naïve patients with first-episode schizophrenia
  22. A longitudinal study on physiological stress in individuals at ultra high-risk of psychosis
  23. Sleep disturbances and the association with attenuated psychotic symptoms in individuals at ultra high-risk of psychosis
  24. Premorbid functioning in adolescence associates with comorbid disorders in individuals at ultra‐high risk for psychosis: A brief report
  25. Normative modeling of brain morphometry in Clinical High-Risk for Psychosis
  26. White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis
  27. Premorbid adjustment associates with cognitive and functional deficits in individuals at ultra-high risk of psychosis
  28. Neuroanatomical heterogeneity and homogeneity in individuals at clinical high risk for psychosis
  29. Cortico-cognition Coupling in Treatment Resistant Schizophrenia
  30. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
  31. Cortico-Cognition Coupling in Treatment Resistant Schizophrenia
  32. Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis
  33. Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra‐high risk for psychosis
  34. Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis
  35. Thinner cortex is associated with psychosis onset in individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group mega-analysis
  36. Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning
  37. Effectiveness of cognitive remediation in the ultra‐high risk state for psychosis
  38. No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial
  39. Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial
  40. Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition
  41. Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states
  42. The 2019 Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: A summary of topics and trends
  43. Predictors of remission from the ultra‐high risk state for psychosis
  44. Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC)
  45. Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis
  46. Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months
  47. Development of Executive Functions as Reflected in Daily Life Behaviors in Young Adults at Ultra-High Risk for Psychosis: Associations With Symptoms and Functioning
  48. Basic symptoms influence real‐life functioning and symptoms in individuals at high risk for psychosis
  49. Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra‐high risk for psychosis
  50. Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis
  51. Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies
  52. T16. GLUTAMATERGIC CHANGES IN UHR
  53. Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition
  54. The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review
  55. Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis
  56. Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?